找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affect; Proceedings of the T Joel Morganroth,

[复制链接]
楼主: CLIP
发表于 2025-3-27 00:49:39 | 显示全部楼层
发表于 2025-3-27 03:13:02 | 显示全部楼层
发表于 2025-3-27 06:19:24 | 显示全部楼层
What Should be Required for FDA Approvability of a New Antihypertensive Drug? What is the FDA’s Viewe fairly clear. Antihypertensive drugs are approved on the basis of a demonstrated ability to lower blood pressure to a reasonable degree and a reasonably complete characterization of a drug’s pharmacokinetic and pharmacodynamic properties, with particular emphasis on dose-response and on patient ch
发表于 2025-3-27 12:24:55 | 显示全部楼层
发表于 2025-3-27 15:36:50 | 显示全部楼层
发表于 2025-3-27 20:24:27 | 显示全部楼层
发表于 2025-3-27 21:56:05 | 显示全部楼层
0166-9842 al and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering
发表于 2025-3-28 03:02:29 | 显示全部楼层
发表于 2025-3-28 06:40:30 | 显示全部楼层
What Should be Required for FDA Approvability of a New Antihypertensive Drug? What is the FDA’s Viewaracteristics that can alter this response. We have not, up to now, sought evidence of diminished end-organ damage or mortality for each new agent, relying instead on the past studies that showed such benefits of lowering blood pressure.
发表于 2025-3-28 13:46:51 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-5 15:54
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表